Proceedings on Cancer-Immuno-Oncology, Vol 1 No 1 (2018)
Creators: name: Wollenberg, Barbara
Publisher: name: Proceedings on Cancer-Immuno-Oncology
Year: 2018

description: Human leukocyte antigens and haplotypes allow for prognostic classification of HNSCC patients...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810001 • DOI: 10.18416/CIO.2018.1810001
Breaking the brake: targeting the immunosuppressive cells to optimize immunotherapy of cancer...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810002 • DOI: 10.18416/CIO.2018.1810002
Immunotherapy and head and neck cancer: Focus on recurrent and metastatic disease...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810004 • DOI: 10.18416/CIO.2018.1810004
Extracellular Vesicles as biomarkers for cancer progression and cancer associated VTE...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810005 • DOI: 10.18416/CIO.2018.1810005
Immune modulation by extracellular vesicles released from mesenchymal cells...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810006 • DOI: 10.18416/CIO.2018.1810006
CAR NK cells for cancer retargeting...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810009 • DOI: 10.18416/CIO.2018.1810009
Immune biological rationale for the design of radioimmunotherapies...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810010 • DOI: 10.18416/CIO.2018.1810010
Role of resident memory T cells in cancer immunotherapy...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810011 • DOI: 10.18416/CIO.2018.1810011
Perspectives of human gamma/delta T-cells in cancer immunotherapy...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810012 • DOI: 10.18416/CIO.2018.1810012
On the development of personalized cancer vaccines...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810013 • DOI: 10.18416/CIO.2018.1810013
Platelets regulate innate immunity in autoinflammatory diseases and cancer...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810014 • DOI: 10.18416/CIO.2018.1810014
A pan-cancer landscape of interactions between tumors and infiltrating immune cells...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810015 • DOI: 10.18416/CIO.2018.1810015
Tumor and host factors regulating anti-tumor immunity and immotherapy efficacy...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810019 • DOI: 10.18416/CIO.2018.1810019
MDSC as a new target for cancer immunotherapy...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810022 • DOI: 10.18416/CIO.2018.1810022
Neo-adjuvant checkpoint inhibition – the pathway towards personalized immunotherapy...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810023 • DOI: 10.18416/CIO.2018.1810023
Interference between tumor mutational burden, HPV status, immune signatures and outcome in patients with head and neck cancer treated with chemoradiotherapy: Results from a multicenter retrospective study of the German Cancer Consortium Radiation Oncology...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810024 • DOI: 10.18416/CIO.2018.1810024
Dynamics of conversation: Immunotherapy meets tumor microenvironment...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810025 • DOI: 10.18416/CIO.2018.1810025
Modulating the tumor microenvironment...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810027 • DOI: 10.18416/CIO.2018.1810027
Rediscovering an old story: HLA class I alterations and immune escape of tumors in the context of immunotherapies...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810029 • DOI: 10.18416/CIO.2018.1810029
Integrin β4 synergizes with E-and P-selectin to regulate tumor growth: Unravelling the molecular mechanisms...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810033 • DOI: 10.18416/CIO.2018.1810033
Primary and recurrent head and neck squamous carcinomas are strikingly different regarding their immune microenvironment...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810035 • DOI: 10.18416/CIO.2018.1810035
The role of NFATc1 in T cell-mediated immune responses during the development of lung cancer...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810036 • DOI: 10.18416/CIO.2018.1810036
Role of glycolysis for intestinal inflammation and carcinogenesis...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810037 • DOI: 10.18416/CIO.2018.1810037
MALDI-imaging: Identification of protein signatures of genomic instability in colorectal cancers...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810039 • DOI: 10.18416/CIO.2018.1810039
Investigating a potential role of Got1 in T cell exhaustion....Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810040 • DOI: 10.18416/CIO.2018.1810040
Biparatopic heavy chain antibodies (bi-hcAbs): fusion of two distinct CD38-specific nanobodies into a human IgG1 bi-hcAb results in potent CDC vs. myeloma cells...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810041 • DOI: 10.18416/CIO.2018.1810041
Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810042 • DOI: 10.18416/CIO.2018.1810042
Effect of both PD-1/PD-L1 and ERK inhibitor on Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810043 • DOI: 10.18416/CIO.2018.1810043
Effect of both PD-1/PD-L1 and ERK inhibitor on triple negative breast cancer cell lines and the non-triple negative cell line MCF-7...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810044 • DOI: 10.18416/CIO.2018.1810044
Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810045 • DOI: 10.18416/CIO.2018.1810045
Specific targeting of oncogenic mutations using CRISPR-technology to destroy activated oncogenes and enhance immune response...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810046 • DOI: 10.18416/CIO.2018.1810046
Effects of EGFR-MEK-ERK pathway on PD-L1 expression in head and neck squamous cell carcinoma...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810047 • DOI: 10.18416/CIO.2018.1810047
The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810048 • DOI: 10.18416/CIO.2018.1810048
CD8+ T cell response to HPV16 E7 predicts survival outcome in oropharyngeal cancer...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810050 • DOI: 10.18416/CIO.2018.1810050
Current status of radiotherapy/radiochemotherapy and immunotherapy combinations– a German survey...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810051 • DOI: 10.18416/CIO.2018.1810051
Activation of immune response in refractory patients to standard treatment (T.R.A.N.S.L.A.T.E.)...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810052 • DOI: 10.18416/CIO.2018.1810052
Which adjuvants for tumor-antigen vaccination induce powerful non-sialylated IgG antibodies?...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810053 • DOI: 10.18416/CIO.2018.1810053
Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810055 • DOI: 10.18416/CIO.2018.1810055
Pre- and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810056 • DOI: 10.18416/CIO.2018.1810056
Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810057 • DOI: 10.18416/CIO.2018.1810057
Robust GMP manufacturing process with IL-2 and a glycoprotein antibody cocktail generates highly active human NK cell batches for cancer immunotherapy...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810058 • DOI: 10.18416/CIO.2018.1810058
Progression of head and neck cancer is associated with elevated neutrophil extracellular traps formation by circulating neutrophils...Proceedings on Cancer-Immuno-Oncology, Vol 1, No 1, 2018 • Article ID: 1810059 • DOI: 10.18416/CIO.2018.1810059